| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 |
| | 10-K | 10-K | 10-K | S-1 |
| Operating activities | | | | |
| Net loss | | | | -178.6 |
| |
| Adjustments to reconcile net loss to net cash used for operating activities: | | | | |
| Depreciation and amortization | | | | 3.8 |
| Amortization of debt issuance costs and debt discount | | | | 15.0 |
| Stock-based compensation | | | | 4.3 |
| Loss (gain) on derivative liability | | | | 23.3 |
| Changes in operating assets and liabilities: | | | | |
| Accounts receivables, net | | | | -12.4 |
| Inventory | | | | -1.1 |
| Accounts payable | 2.8 | -3.8 | -4.1 | 4.3 |
| Accrued Payroll | | | | 1.1 |
| Accrued expenses | 2.7 | -3.2 | -5.1 | 9.1 |
| Other liabilities | | | | -0.1 |
| Related party payable | 30.1 | 18.2 | 5.1 | 1.9 |
| Net cash used for operating activities | -21.3 | -28.7 | -31.5 | -60.4 |
| |
| Investing activities | | | | |
| Purchase of property, plant, and equipment | 0.0 | | 0.0 | -0.6 |
| Net cash used for investing activities | -2.1 | | 0.0 | -17.6 |
| |
| Financing activities | | | | |
| Proceeds from stock options and warrants exercised | 0.1 | | 0.1 | |
| Proceeds from related party payable | 51.9 | 47.9 | 18.4 | |
| Net cash proceeds from financing activities | 21.2 | 28.2 | -19.2 | 15.8 |
| |
| Supplemental disclosure: | | | | |
| Supplemental disclosure of non-cash financing activity | | | | |
| Related party debt converted to equity | | | | |
| Non-cash Consideration in Semnur Acquisition | | | | |
| Other Loan Forgiveness | | | | |
| Acquisition of right-of-use asset | | | | |
| Live Action right-of-use asset in Palo Alto | | | | |
| Non-cash distribution to Sorrento | | | | |
| Issuance of shares to Yorkville | | | | |
| Scilex Pharma Notes principal increase | | | | |
| Scilex Pharma Notes principal increase | | | | |
| Accrual for transaction costs related to the Business Combination | | | | |
| Transaction costs obligation assumed by Sorrento | | | | |
| Deferred underwriting fee payable | | | | |
| Offering costs included in accrued offering costs | | | | |